( OTC-PINK:RXII, OTC-QB:RXII )

News from RXi Pharmaceuticals Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 13, 2017, 07:05 ET RXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics, and Gustave Roussy, a...


Nov 08, 2017, 07:05 ET RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Nov 07, 2017, 07:05 ET RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Nov 01, 2017, 07:05 ET RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


Oct 11, 2017, 07:05 ET RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Sep 19, 2017, 07:05 ET RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Sep 18, 2017, 07:05 ET RXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Sep 15, 2017, 16:30 ET RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Sep 15, 2017, 07:05 ET BioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury

BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (NASDAQ: RXII), it is the...


Sep 06, 2017, 07:05 ET RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 31, 2017, 07:05 ET RXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 10, 2017, 07:05 ET RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 09, 2017, 07:05 ET RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15.0 Million

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 08, 2017, 07:05 ET RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 03, 2017, 08:05 ET RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing Requirements

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Aug 03, 2017, 07:05 ET RXi Pharmaceuticals to Webcast Second Quarter 2017 Financial Results on Thursday, August 10, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


Jun 21, 2017, 07:05 ET RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


Jun 12, 2017, 07:05 ET RXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Jun 08, 2017, 07:05 ET RXi Pharmaceuticals to Present at the Marcum MicroCap Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Jun 07, 2017, 07:05 ET RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


May 23, 2017, 07:05 ET RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 22, 2017, 07:05 ET PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology

PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on...


May 11, 2017, 07:05 ET RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 04, 2017, 07:02 ET RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 02, 2017, 07:02 ET RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...